Skin disorders in Parkinson's disease:potential biomarkers and risk factors by Ravn, Astrid-Helene et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Skin disorders in Parkinson's disease
Ravn, Astrid-Helene; Thyssen, Jacob P; Egeberg, Alexander
Published in:
Clinical. Cosmetic and Investigational Dermatology
DOI:
10.2147/CCID.S130319
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Ravn, A-H., Thyssen, J. P., & Egeberg, A. (2017). Skin disorders in Parkinson's disease: potential biomarkers
and risk factors. Clinical. Cosmetic and Investigational Dermatology, 10, 87-92.
https://doi.org/10.2147/CCID.S130319
Download date: 03. Feb. 2020
© 2017 Ravn et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Clinical, Cosmetic and Investigational Dermatology 2017:10 87–92
Clinical, Cosmetic and Investigational Dermatology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
87
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CCID.S130319
Skin disorders in Parkinson’s disease: potential 
biomarkers and risk factors
Astrid-Helene Ravn
Jacob P Thyssen
Alexander Egeberg
Department of Dermatology and 
Allergy, Herlev and Gentofte Hospital, 
University of Copenhagen, Hellerup, 
Denmark
Abstract: Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, 
characterized by a symptom triad comprising resting tremor, rigidity, and akinesia. In addition, 
non-motor symptoms of PD are well recognized and often precede the overt motor manifestations. 
Cutaneous manifestations as markers of PD have long been discussed, and cumulative evidence 
shows an increased prevalence of certain dermatological disorders in PD. Seborrheic dermatitis 
is considered to occur as a premotor feature of PD referable to dysregulation of the autonomic 
nervous system. Also, an increased risk of melanoma has been observed in PD. Light hair color 
is a known risk factor for melanoma, and interestingly the risk of PD is found to be significantly 
higher in individuals with light hair color and particularly with red hair. Furthermore, several 
studies have reported a high prevalence of PD in patients with bullous pemphigoid. Moreover, 
a 2-fold increase in risk of new-onset PD has been observed in patients with rosacea. Besides 
the association between PD and various dermatological disorders, the skin may be useful in the 
diagnosis of PD. Early PD pathology is found not only in the brain but also in extra-neuronal 
tissues. Thus, the protein α-synuclein, which is genetically associated with PD, is present not 
only in the CNS but also in the skin. Hence, higher values of α-synuclein have been observed 
in the skin of patients with PD. Furthermore, an increased risk of PD has been found in the Cys/
Cys genotype, which is associated with red hair color. In this review, we summarize the current 
evidence of the association between PD and dermatological disorders, the cutaneous adverse 
effects of neurological medications, and describe the potential of skin protein expression and 
biomarkers in identification of risk and diagnosis of PD.
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Introduction
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders,1 
affecting ~0.3% of the general population in industrialized countries.1 Although the 
pathogenesis of PD is not yet fully understood, the selective loss of dopaminergic neurons 
is believed to play a crucial role in disease onset and progression. Explanatory theories 
include mitochondrial dysfunction, oxidative stress, and protein mishandling.1 Moreover, 
although most cases occur sporadically, several genetic mutations, for example, in the 
Parkin (PARK2) and PINK1 (PARK6) genes have also been associated with the disease.2
PD is characterized by a symptom triad comprising resting tremor, rigidity, and 
akinesia. In addition, non-motor symptoms of PD are well recognized and often pre-
cede the overt motor manifestations.3 The non-motor symptoms of PD include sleep 
disorders, constipation, bladder problems, excessive saliva, depression, apathy, fear 
and anxiety, and cutaneous problems.3
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The latter have been discussed since the beginning of 
the 20th century, and cumulative evidence suggests a causal 
association between the neurological disturbance in PD and 
associated cutaneous manifestations.4 Despite the idea that 
certain dermatological disorders are frequent non-motor 
symptoms of PD, and potentially add to the impaired qual-
ity of life in these patients, these often go unnoticed by the 
treating physicians.4
Attention should be paid to PD-associated skin disorders 
as they affect the psychosocial well-being of the patients. It 
is, therefore, important to correctly diagnose and treat the 
disorders to improve the patients’ quality of life.
In this review, we summarize the current evidence of 
dermatological disorders in patients with PD, outline selected 
cutaneous adverse effects of anti-PD medications, and discuss 
how objective skin changes can serve as a diagnostic tool in PD.
The PubMed and Medline databases were searched (Sep-
tember 2016) to identify studies investigating PD-associated 
skin disorders. The references of the eligible literature were 
assessed to identify additional relevant studies.
Skin conditions in PD
Seborrheic dermatitis
Seborrheic dermatitis is a common chronic inflammatory 
skin disorder, affecting ~1%–3% of the general population 
(Figure 1).5 It is primarily located to sebum-rich areas, such 
as the scalp, face, hairline, eyebrow, glabella, nasolabial folds, 
ears, upper chest, and in skin folds under arms and on legs. 
The incidence of seborrheic dermatitis peaks in certain age 
groups, that is, infants up to 3 months old, during puberty, 
and in adulthood.6 In all age groups, an incidence of 3.0% is 
found in men vs. 2.6% in women, thus, suggesting a patho-
genic role of certain sex hormones.7
The increased production of host sebum as well as the 
presence and increased reproduction of Malassezia yeasts are 
the two major factors believed to contribute to the develop-
ment of SD.4,8 Seborrhea has been associated with PD, with 
a prevalence as high as 52%–59%.8 In 1927, Krestin reported 
seborrheic facies as a cutaneous manifestation of parkin-
sonism, particularly in post-encephalic parkinsonism,9 and 
described the skin as shiny, greasy, and with characteristic 
scarring acne. In a retrospective study on the association 
between seborrheic dermatitis and PD, Tanner et al proposed 
that seborrheic dermatitis might represent a premotor feature 
of PD, ascribable to autonomic nervous system dysregulation, 
and suggested that seborrheic dermatitis could serve as an 
early disease marker of PD.10 Appropriate anti-fungal treat-
ment, such as ketoconazole can be useful for PD patients, 
as such agents may reduce Malassezia growth and enzyme 
production. Anti-inflammatory agents in the form of topical 
steroids or topical calcineurin inhibitors can also be used 
in the treatment, thus improving patient’s well-being and 
quality of life.
Melanoma
Melanoma is a skin cancer arising from epidermal mela-
nocytes (Figure 2). Risk factors for melanoma comprise 
a combination of constitutional predisposition (fair skin, 
blond or red hair, freckles, family history of melanoma, 
high number of nevi, and increasing age) and exposure to 
ultraviolet radiation.11,12
The exact risk of melanoma in PD remains unclear. A 
connection was first suspected following a number of case 
reports, suggesting that levodopa therapy might increase the 
risk of melanoma.13 However, this finding was later ques-
tioned after reviews of these case reports concluded that the 
link was coincidental rather than causal.14–16 Nevertheless, 
Figure 1 Seborrheic dermatitis. Figure 2 Malignant melanoma.
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studies in favor of a possible association between PD and 
melanoma have been published. A large Danish study of 
>14,000 patients with PD concluded that an increased rate 
of melanoma was restricted to those with idiopathic PD and 
unrelated to levodopa treatment.17 Similarly, a prospective 
study including 2106 patients from North America found 
a 2-fold higher melanoma prevalence in patients with PD 
compared with the general population,18 yet a large meta-
analysis only found a moderate association between the two 
conditions.19
The explanation for a potential link between melanoma 
and PD is unclear, but various hypotheses have been put 
forward. α-Synuclein, an enzyme that inhibits tyrosine 
hydroxylase, is involved in the melanin synthesis in both 
melanoma and dopaminergic neuronal cells in PD and 
could be one plausible explanation.20 Moreover, while light 
hair color is a risk factor for melanoma, a prospective study 
including 132,302 health care professionals,21 found that 
risk of PD increased significantly with decreasing darkness 
of hair color. Indeed, red-haired individuals had an ~2-fold 
higher PD risk compared with black-haired individuals. 
Furthermore, an association between hair color and early-
onset PD (<70 years) was also observed, whereas hair color 
was not significantly associated with risk of PD onset after 
the age of 70 years. Although the exact cause remains to be 
elucidated, differences in pigment metabolism may explain 
the observed association of PD with lighter hair colors.21 
Consequently, physicians could advise patients with PD, 
in particular those with lighter skin tones, on the possible 
augmented melanoma risk and encourage them to remain 
vigilant about any new, or changing pigmented skin lesions. 
Furthermore, emphasis on the importance of sun protection, 
including limiting exposure and using high-factor sun block-
ing agents, could be valuable.22
Bullous pemphigoid
Bullous pemphigoid (BP) is a bullous autoimmune skin dis-
ease, affecting elderly people with a median age of 80 years 
(Figure 3).23,24 The condition is characterized by pruritus and 
tense cutaneous bullae on erythematous skin and is associated 
with significantly increased mortality rates compared with 
the general population.24,25 The pathogenesis of BP includes 
the development of autoantibodies against skin antigens,24 
but the pathogenic link with PD remains poorly understood. 
Several retrospective studies have reported associations 
between previous neurological diseases, including PD, and 
the later development of BP. In a study by Cordel et al,26 
PD was observed in 32 (9%) of 341 patients with BP. The 
association was also found in a population-based case–con-
trol study including 868 patients with BP and 3453 controls 
where PD was present in 26 cases (3%) and in 36 controls 
(1%),24 and similar findings were reported in a retrospective 
study from Olmsted County, MN.25 Along this line, a Spanish 
case–control study, including 56 patients with BP and 112 
control subjects, reported a PD prevalence of 17.9% and 
3.6% among BP patients and controls, respectively.27 Finally, 
a multi-center case–control study evaluating the risk factors 
for BP in elderly people found PD present in 14.3% of BP 
cases compared with only 5.8% control subjects.28 As BP 
increases mortality and affects the psychosocial well-being, 
it is important to correctly diagnose and treat the disease to 
improve the patients’ quality of life.
Rosacea
Rosacea, a common facial skin dermatosis, is characterized 
by the features of neurogenic inflammation, such as transient 
or persistent facial erythema, edema, burning pain, immune 
infiltration, telangiectasia, papules, and pustules, and has an 
estimated prevalence ranging from 1% to 20% (Figure 4).29,30 
Emerging evidence suggests a possible association between 
rosacea and PD.31–33 In a study by Fischer et al,31non-invasive 
bioengineering methods (sebumetry, corneometry, pH involv-
ing 70 patients with PD, rosacea was present in 18.6%, and 
flushing symptoms were found in 31.9% of patients. The 
Figure 3 Bullous pemphigoid.
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overlap between the facial flushing occurring in PD due to 
autonomic dysregulation and the facial flushing experienced 
in patients with rosacea was noted as a complicating factor in 
the diagnosis of concurrent rosacea and PD. Importantly, in 
a nationwide Danish cohort study of >4,000,000 individuals, 
an ~2-fold increase in risk of new-onset PD was observed in 
patients with rosacea.32 This finding was very recently repli-
cated in a US cohort using electronic medical record linkage of 
803,005 individuals, including 17,682 patients with rosacea.33
Although the pathogenic link between rosacea and PD 
has not yet been fully determined, shared pathogenic mecha-
nisms involving elevated matrix metalloproteinase activity 
have been suggested.32 In addition, studies have observed 
a decreased density of cutaneous nerve fibers in the early 
and late stages of PD.34 This dysfunction of sensory nerve 
fibers contributes to the release of a sectional immune reac-
tion, following the activation of the immune response. This 
immune destabilization is believed to result in occurrence of 
opportunistic skin disorders in vulnerable areas of the skin.35 
As non-motor symptoms often precede the motor symptoms 
in PD, it is possible that PD may foreword the clinical mani-
festation of rosacea. Therefore, rosacea may constitute an 
independent risk factor for PD and vice versa.35 The gastro-
intestinal system has also been proposed as a link between 
the two conditions. As the entire gastrointestinal tract (GIT) 
is affected in patients with PD, increasing evidence indicates 
that the GIT indeed might be the site of disease initiation.36 
Moreover, persistent infection with small intestine bacterial 
overgrowth and Helicobacter pylori may contribute to the 
pathogenesis.37 Although speculative, the recent observations 
could suggest that cutaneous rosacea features may be an early 
disease marker of PD in certain patients.
Cutaneous adverse effects of 
neurological medications
While allergic cutaneous reactions to dopaminergic drugs 
are very rare, few cases of skin rashes have been reported 
following the use of Sinemet® (carbidopa/levodopa) com-
pounded with yellow dye. As rashes were not reported with 
other tablet sizes of this drug containing blue dye, the yellow 
dye used in that specific preparation was suspected as the 
offending compound.4,38 The cases reported maculo-papular 
rashes on the trunk and arms, which resolved following 
discontinuation of carbidopa/levodopa and reoccurred when 
the drug was reintroduced.
Symmetrel® (Amantaine), a primary amine originally 
used as an antiviral chemotherapeutic, was later found effica-
cious as an anti-Parkinson agent. The drugs have been known 
to cause a mottled reticulated vascular pattern, termed livedo 
reticularis (LR), which is predominantly localized on the 
lower extremities.39 The exact cause of the development of 
LR following or during treatment with amantadine remains 
unclear, but may be due to interruption of the peripheral 
blood redistribution, particularly in the dermal arteries and 
peripheral vasospasms which lead to LR. Ergoline, a chemi-
cal compound used in certain dopamine agonists have been 
associated with erythromelalgia, a rare neurovascular skin 
disorder that usually affects the palms and soles of the hands 
and feet. It is characterized by episodes of erythema, swell-
ing, and painful burning sensation. However, these days, 
ergoline dopamine agonists are rarely used for PD, and no 
cases of erythromelalgia have been reported with the use of 
the non-ergoline dopamine agonists.4
As various cutaneous effects may occur following the use 
of anti-PD agents, thorough patient information and regular 
monitoring by treating physicians is advised. Discontinua-
tion of treatment can cause motor symptoms such as tremor 
and dyskinesia, but continued therapy following cutaneous 
reactions may potentially worsen the physical and mental 
conditions of patients with PD. Consequently, a personalized 
treatment approach is, therefore, recommended.
Potential of skin protein expression 
in PD
Beyond PD’s association with various dermatological dis-
orders, the skin is also likely to serve as a helpful tool in 
the diagnosis of PD. α-Synuclein, a presynaptic neuronal 
protein and the main protein component of Lewy bodies, 
is genetically linked with PD. As emerging evidence has 
shown, α-synuclein is not only found in the central nervous 
system but also found in the peripheral autonomic nervous 
system.20 Potential biomarkers allowing for a precise diag-
nosis of synucleinopathies have been investigated in body 
fluids and peripheral tissues, such as salivatory glands, 
the peripheral nervous system, and the skin. However, no 
Figure 4 Rosacea.
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widely accepted diagnostic marker presently exists.40–42 In 
one study, the presence of α-synuclein was analyzed in the 
skin derived from punch biopsies of 17 healthy individuals 
and an identical number patients with PD.43 The study found 
that α-synuclein values were significantly higher in the PD 
group compared with controls. Furthermore, Ikemura et al, 
prospectively examined skin samples from the abdominal 
wall and upper limbs of 279 patients of whom 85 patients 
displayed Lewy Body pathology.44 The authors found dermal 
α-synuclein immunoreactivity in 23.5% of patients with 
Lewy Body pathology. No reactivity was observed in patients 
without Lewy Body pathology. Moreover, Miki et al exam-
ined dermal and subcutaneous tissue samples from the chest 
wall and lower limb of 20 patients with PD.45 Interestingly, 
while abnormal α-synuclein accumulation was observed in 
the dermis of the chest wall, findings from the lower limbs 
were less consistent.
Implications for biomarkers in the 
prediction and early diagnosis of 
Parkinson’s disease
Cumulative cellular damage in patients with PD can be found 
in skin fibroblasts, and the PINK1 and Parkin genes are 
expressed at relevant levels in human fibroblasts.2 Moreover, 
fibroblasts from patients with idiopathic PD show a clear and 
distinctive mRNA expression pattern of key genes in neuro-
degeneration,2 and increased risk of PD is found in specific 
genotypes. For example, a case–control study including 272 
cases and 1185 controls found that participants with the Cys/
Cys genotype had a higher risk of PD.21 This specific genotype 
is associated with red hair, thus suggesting a potential role 
of pigmentation in PD.21
Conclusively, as early pathology is not only found in 
the brain but possibly also in extra-neuronal tissues such as 
the skin, it is tempting to speculate that skin biopsies may 
be used for PD diagnosis in the future.2 In addition, origins 
of skin-derived precursors may serve an alternative source 
of stem cells to embryonic stem cells for transplantation 
therapy for PD.46
Conclusion and future directions
In conclusion, patients with PD may suffer from a variety 
of concurrent or preceding skin disorders. While seborrheic 
dermatitis is considered to occur as a premotor symptom in 
PD, rosacea may constitute a risk factor, or an early sign of 
PD development. Furthermore, strong associations between 
PD and the later development of BP have also been found, 
and a possible link between PD and melanoma has been 
observed. As increased risk of PD and melanoma has been 
found in individuals with light hair color, and particularly 
red hair, treating physicians should show these individuals 
special awareness and emphasize the importance of sun 
protection, including limiting exposure and using high-factor 
sun blocking agents.
Analyses of α-synuclein in skin biopsies show that patho-
physiological examinations of neurodegenerative disorders, 
such as PD, may be successful through investigation of the 
skin. Therefore, skin biopsies may in the future be used in 
the diagnosis of PD. Yet, to better understand the association 
between PD and specific dermatological diseases in general, 
and BP in particular, further studies are required.
As skin disorders represent an important aspect of life 
with PD, awareness and correct treatment of these are impor-
tant in order to improve patients’ everyday life.
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